In our epigenome-wide analysis, nine CpG sites within MAPT yielded significantly different methylation values in PSP vs. controls, which, however, did not hold up to correction for multiple testing (Supplementary Data 3). The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.